About the Journal
About the Journal
Biomedical Innovation and Discovery (BID) is a premier, peer-reviewed, international, and fully open-access scholarly journal dedicated to accelerating the critical transition from foundational laboratory science to tangible, life-saving clinical applications. Launched at the intersection of rapidly evolving biomedical technology and pressing global health needs, the journal serves as a dynamic, interdisciplinary forum for the dissemination of transformative research that redefines the boundaries of health sciences and clinical practice.
Our Mission & Vision
Our mission is to catalyze the next generation of biomedical breakthroughs by providing a high-visibility, rigorous, and accessible platform for pioneering research. We envision a future where scientific discovery is seamlessly integrated into clinical decision-making, and we are committed to being the conduit that connects the laboratory bench to the patient's bedside. By fostering collaboration among basic scientists, translational researchers, clinicians, and industry leaders, Biomedical Innovation and Discovery aims to shorten the translational gap and expedite the delivery of novel therapies, diagnostics, and preventive strategies to populations worldwide.
Scope & Core Focus Areas
The journal casts a wide net over the entire spectrum of biomedical research, with a strategic emphasis on innovation, mechanistic insight, and translational potential. We invite contributions that not only expand the boundaries of human knowledge but also lay the groundwork for tangible improvements in human health. Our core areas of interest include, but are not limited to:
Molecular & Cellular Pathogenesis: In-depth studies elucidating the genetic, epigenetic, and molecular underpinnings of human diseases, including cancer, neurodegenerative disorders, cardiovascular pathologies, metabolic syndromes, infectious diseases, and rare genetic conditions.
Diagnostic & Theranostic Innovation: Development and validation of next-generation biomarkers, liquid biopsies, advanced medical imaging techniques, point-of-care diagnostics, and integrated theranostic platforms that enable early detection, real-time monitoring, and personalized treatment regimens.
Novel Therapeutic Modalities: Preclinical and early-phase clinical research on groundbreaking therapeutic approaches, such as gene therapy, CRISPR-based genome editing, mRNA therapeutics, cell-based immunotherapies (e.g., CAR-T, NK cells), targeted protein degradation (PROTACs), and nanotechnology-enabled drug delivery systems.
Biomaterials, Tissue Engineering, & Regenerative Medicine: Design and application of smart biomaterials, bioprinted constructs, organ-on-a-chip systems, and stem cell-based strategies for tissue repair, organ replacement, and the modeling of human physiology and disease.
Artificial Intelligence & Digital Health: Integration of machine learning, computational biology, bioinformatics, and health informatics to analyze complex biomedical datasets, predict disease trajectories, optimize drug discovery pipelines, and enhance clinical decision-support systems.
Pharmacogenomics & Precision Medicine: Research that dissects inter-individual variability in drug response, enabling the personalization of therapeutic strategies based on a patient's genomic, proteomic, and metabolomic profiles to maximize efficacy and minimize adverse effects.
Translational & Clinical Proof-of-Concept: Rigorous first-in-human, Phase I/II clinical trials, observational studies, and translational feasibility studies that provide critical proof-of-concept data for emerging biomedical interventions, along with pragmatic implementation science that addresses real-world adoption.
Our Commitment to Quality, Integrity, & Impact
Biomedical Innovation and Discovery is distinguished by its unwavering commitment to scientific excellence, reproducibility, and ethical integrity. We maintain a stringent, double-anonymized peer-review process, facilitated by an international editorial board of distinguished experts, ensuring that every published manuscript is methodologically sound, statistically robust, and logically coherent. We actively encourage:
Pre-registration of studies and the submission of negative or null results, as we believe all methodologically valid data contributes to the collective scientific endeavor.
Data transparency and sharing, requiring authors to deposit raw data, code, and protocols in accessible repositories to foster validation, replication, and secondary analysis.
Strict adherence to ethical guidelines for human and animal research, as well as compliance with global standards for biosafety, biosecurity, and the responsible conduct of research.
Open Access & Global Reach
As a fully open-access journal, we remove all paywalls, ensuring that our content is freely and permanently accessible to researchers, clinicians, policymakers, and the public worldwide. This commitment democratizes knowledge and maximizes the visibility, reach, and citation potential of the work we publish. We believe that impactful research should not be hidden behind subscription fees, and our open-access model reflects our dedication to global equity in scientific progress.
A Dynamic Platform for the Scientific Community
Beyond traditional research articles, Biomedical Innovation and Discovery publishes a rich variety of content designed to foster scholarly discourse and professional development. This includes comprehensive review articles, rapid communications, methodological innovations, case studies that highlight novel clinical lessons, and insightful perspectives on the ethical, regulatory, and societal dimensions of biomedical innovation. We also feature special thematic series dedicated to emerging “hot topics,” providing a curated deep-dive into areas of urgent scientific and clinical interest.
